# CRISPR Therapeutics

> company in Basel, Switzerland

**Wikidata**: [Q104480207](https://www.wikidata.org/wiki/Q104480207)  
**Wikipedia**: [English](https://en.wikipedia.org/wiki/CRISPR_Therapeutics)  
**Source**: https://4ort.xyz/entity/crispr-therapeutics

## Summary
CRISPR Therapeutics is a Swiss biotechnology company headquartered in Zug, Switzerland, focused on developing gene therapies using CRISPR technology, and it is publicly traded on the Nasdaq stock exchange.

## Key Facts
- Founded in 2013 by Emmanuelle Charpentier
- Legal form: Aktiengesellschaft
- Industry classification: biotechnology industry
- Headquarters location: Zug, Switzerland (coordinates: 47.552527, 7.593099)
- Listed on Nasdaq stock exchange (ticker: CRSP)
- Website: http://www.crisprtx.com/
- Twitter handle: crisprtx (social media followers: 19,367 as of 2023-02-06)
- ISIN: CH0334081137
- ROR ID: 04ewmsk50
- Country: Switzerland
- Legal entity identifier: 506700O6IRRIQLT3W370
- Scilit organization ID: 98676
- Crunchbase organization ID: crispr-therapeutics
- Wikipedia languages: German, English, Persian
- Wikidata description: company in Basel, Switzerland
- Grid ID: grid.509081.5
- Central index key: 0001674416

## FAQs
**What is CRISPR Therapeutics' primary business?**
It is a biotechnology company focused on developing gene therapies using CRISPR technology.

**Where is the company headquartered?**
The company's headquarters is in Zug, Switzerland.

**Who founded CRISPR Therapeutics?**
The company was founded by Emmanuelle Charpentier.

**What stock exchange does it trade on?**
CRISPR Therapeutics is publicly traded on the Nasdaq stock exchange under ticker symbol CRSP.

**What is its legal structure?**
The company operates as an Aktiengesellschaft (AG), a type of corporation in Switzerland.

**What is the company's website?**
Its official website is http://www.crisprtx.com/.

## Why It Matters
CRISPR Therapeutics represents a significant advancement in the field of gene therapy, leveraging CRISPR-Cas9 technology to develop treatments for genetic diseases. The company's work addresses the challenge of precisely editing human DNA to correct genetic mutations, potentially providing curative treatments for previously untreatable conditions. As a publicly traded biotechnology firm, it plays a crucial role in translating scientific breakthroughs into commercial medical solutions, contributing to the broader biotechnology industry's growth and innovation.

## Notable For
*   Being a pioneer in developing CRISPR-based gene therapies
*   Operating as a public company with Nasdaq listing since 2016
*   Having Emmanuelle Charpentier as a founder, who won the Nobel Prize in Chemistry in 2020 for her work on CRISPR
*   Developing treatments for genetic diseases through precise genome editing
*   Maintaining a presence on multiple social media platforms and international Wikipedia editions

## Body
### History and Founding
CRISPR Therapeutics was established in 2013 as a Swiss biotechnology company. The organization was founded by Emmanuelle Charpentier, a key figure in the development of CRISPR-Cas9 technology. The company's inception marked the beginning of commercial efforts to translate CRISPR research into therapeutic applications.

### Leadership and Governance
The company operates under the legal form of an Aktiengesellschaft (AG), a standard corporate structure in Switzerland. The leadership includes a board of directors elected by shareholders, with governance following the separation of ownership and control typical of public corporations.

### Operations and Location
CRISPR Therapeutics is headquartered in Zug, Switzerland, with additional operations likely in Basel as referenced in its Wikidata description. The company maintains a website at http://www.crisprtx.com/ and has a Twitter presence under the handle @crisprtx, with approximately 19,367 followers as of February 2023.

### Financial and Market Status
As a public company, CRISPR Therapeutics is listed on the Nasdaq stock exchange under the ticker symbol CRSP. The company's stock is identified by the central index key 0001674416 and the ISIN CH0334081137. Its ROR ID is 04ewmsk50, and it has a Crunchbase organization ID of crispr-therapeutics.

### Industry Classification and Identification
The company is classified within the biotechnology industry and is recognized by various organizational identifiers including a Scilit organization ID of 98676 and a legal entity identifier of 506700O6IRRIQLT3W370.

### Global Presence and Recognition
CRISPR Therapeutics is recognized internationally, with presence documented in multiple languages including German, English, and Persian on Wikipedia. The company's work is tracked by academic and financial resources, appearing in references such as ScienceDirect under economics-econometrics-and-finance/public-company topics and Investopedia's coverage of biotechnology companies.

### Technical Focus and Products
The company specializes in developing gene therapies that utilize CRISPR technology to precisely edit human DNA. This approach aims to treat genetic diseases by correcting underlying mutations rather than managing symptoms. The specific therapeutic products and clinical trials are not detailed in the provided source material, but the company's mission centers on this revolutionary genome editing technology.

## References

1. GRID Release 2020-12-09
2. Google Knowledge Graph
3. Polygon.io
4. Global LEI Index
5. ROR Data Dump 8.0 (April 2021)
6. [Source](https://golden.com/wiki/CRISPR_Therapeutics-R9D5DXK)